Profile
Stephen Dowd worked as a Senior Director of Business Development at Kymab Ltd., a Team Leader at GSK Plc, and a Senior Business Development Manager at Arecor Ltd.
He also served as the Head of Business Development at Rallybio Corp.
from 2021 to 2023.
Dr. Dowd holds an MBA from the University of Cambridge and a doctorate from the University of Dundee.
Former positions of Stephen Dowd
Companies | Position | End |
---|---|---|
RALLYBIO CORPORATION | Corporate Officer/Principal | 01/09/2023 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
GSK PLC | Corporate Officer/Principal | - |
Arecor Ltd.
Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Training of Stephen Dowd
University of Cambridge | Masters Business Admin |
University Of Dundee | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
GSK PLC | Health Technology |
RALLYBIO CORPORATION | Health Technology |
Private companies | 2 |
---|---|
Arecor Ltd.
Arecor Ltd. BiotechnologyHealth Technology Arecor Ltd. provides stabilization technology solutions. The firm's products include ultra-rapid acting prandial insulin, stable aqueous glucagon, ultra concentrated insulin and additional programs. The company was founded by Paul James Davis in 2007 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Stephen Dowd